Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMY) is dated November 15, 2019. The report addresses an extension of the expiration date for previously announced Exchange Offers and Consent Solicitations related to Celgene Corporation notes, which are part of the planned acquisition of Celgene.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figure disclosed relates to the debt exchange program:
- Aggregate Principal Amount of New Notes: Up to $19,850,000,000.
Material Changes
The primary material change reported is the extension of the expiration date for the Exchange Offers and Consent Solicitations regarding Celgene Notes:
- Previous Expiration Date: November 15, 2019, at 5:00 p.m. New York City time.
- New Expiration Date: November 20, 2019, at 5:00 p.m. New York City time.
- Future Extensions: The Expiration Date may be further extended one or more times, with notice provided in advance.
Guidance, Outlook, and Risks
Merger Timeline: The closing of the Merger with Celgene is expected to occur by the end of 2019. The settlement of the Exchange Offers is expected to occur promptly after the Expiration Date and on or about the Merger closing date.
Conditions: The Exchange Offers and Consent Solicitations are conditioned upon the closing of the Merger, a condition that cannot be waived by Bristol-Myers Squibb. Supplemental indentures executed on May 1, 2019, will only become operative upon the settlement date.
Risks and Contingencies: The filing notes that the Expiration Date may be extended further depending on the Merger timeline. No other specific risks or unusual items are detailed in this specific text.
Investor Verification Checklist
- Verify the final closing date of the Celgene Merger to confirm if the November 20, 2019, deadline is met or if further extensions are announced.
- Confirm the final settlement date of the Exchange Offers once the Merger closes.
- Review the attached press release (Exhibit 99.1) for detailed terms of the Amendments to the Celgene Notes indentures.
- Monitor for any additional 8-K filings regarding further extensions of the Expiration Date.